Dear Colleagues,

On behalf of the Organizing Committee, we warmly invite you to the 29th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (XXIX IACRLRD Symposium, IACRLRD 2019) to be held in Grand Hyatt Seoul, Korea from November 7 to 9, 2019.

As the world’s leading platform for the exchange of ideas and knowledge for researchers of comparative research on leukemia and related diseases, IACRLRD 2019 will feature highly-renowned speakers, a stimulating scientific program and various opportunities for participants to network and build collaborative relationships.

The Korean Society of Hematology (KSH) and IACRLRD World Committee are delighted to be the hosts and will go to great lengths to ensure that the symposium surpasses all expectations.

We encourage you to mark the important dates in your calendar and follow our updates on the IACRLRD 2019 website.

We look forward to seeing you at IACRLRD 2019 in Seoul, Korea.

Dong-Wook Kim, M.D., Ph.D.
Chair of IACRLRD 2019
President of IACRLRD

Giuseppe Saglio, M.D., Ph.D.
Secretary General,
IACRLRD

Bin Cho, M.D., Ph.D.
President,
The Korean Society of Hematology

Chan-Jeoung Park, M.D., Ph.D.
Congress Chair,
The Korean Society of Hematology
LOCAL ORGANIZING COMMITTEE

<table>
<thead>
<tr>
<th>Chair of IACRLRD 2019</th>
<th>Dong-Wook Kim</th>
<th>The Catholic University of Korea, College of Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>President of IACRLRD</td>
<td>Bin Cho</td>
<td>The Catholic University of Korea, College of Medicine</td>
</tr>
<tr>
<td>Congress Chair of KSH</td>
<td>Chan-Jeoung Park</td>
<td>University of Ulsan College of Medicine</td>
</tr>
<tr>
<td>Vice Chair of IACRLRD 2019</td>
<td>Keon Hee Yoo</td>
<td>Sungkyunkwan University School of Medicine</td>
</tr>
<tr>
<td>Advisory Committee Chair</td>
<td>Jin Seok Kim</td>
<td>Yonsei University College of Medicine</td>
</tr>
<tr>
<td>Finance Committee Chair</td>
<td>Seongsoo Jang</td>
<td>University of Ulsan College of Medicine</td>
</tr>
<tr>
<td>Scientific Committee Chairs</td>
<td>Hyo Jung Kang</td>
<td>Seoul National University College of Medicine</td>
</tr>
<tr>
<td></td>
<td>Hongtae Kim</td>
<td>Ulsan National Institute of Science and Technology</td>
</tr>
<tr>
<td>Scientific Committee Members</td>
<td>Dong Yeop Shin</td>
<td>Seoul National University College of Medicine</td>
</tr>
<tr>
<td></td>
<td>Hyery Kim</td>
<td>University of Ulsan College of Medicine</td>
</tr>
<tr>
<td></td>
<td>Jae wook Lee</td>
<td>The Catholic University of Korea, College of Medicine</td>
</tr>
<tr>
<td></td>
<td>Joo Yong Lee</td>
<td>Chungnam National University</td>
</tr>
<tr>
<td></td>
<td>Yang-Woo Jung</td>
<td>Korea University College of Pharmacy</td>
</tr>
<tr>
<td></td>
<td>Yoon Sung Lee</td>
<td>Institute for Basic Science</td>
</tr>
<tr>
<td>Planning Committee Chair</td>
<td>Seung-Ah Yahng</td>
<td>The Catholic University of Korea, College of Medicine</td>
</tr>
<tr>
<td>Public Relations Committee Chair</td>
<td>Meerim Park</td>
<td>National Cancer Center</td>
</tr>
</tbody>
</table>

KEY SPEAKERS

Infectious Origins of Some Leukemias & What To Do

Prof. Robert Gallo
University of Maryland, USA

Leukemia Stem Cell and Bone Marrow Microenvironment Interactions

Prof. Ravi Bhatia
The University of Alabama at Birmingham, USA

Biological Heterogeneity of AML: Implications for Prognosis and Treatment

Prof. Clara Bloomfield
The Ohio State University, USA

Integrating CART-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes

Prof. David G. Maloney
Fred Hutchinson Cancer Research Center, USA

Understanding Evolution and Outcomes in Myeloproliferative Neoplasms

Dr. Jyoti Nangalia
Wellcome Sanger Institute, UK

Translating DNA Repair for Targeting Cancers

Prof. Kyungjae Myung
UNIST / Institute for Basic Science, Korea

Approaching Survival of the General Population: The Results of CML Study IV in the Global Context

Prof. Rüdiger Hehlmann
Heidelberg University, Germany

New Models of Human Leukemia

Dr. Connie Eaves
British Columbia Cancer Agency, Canada
<table>
<thead>
<tr>
<th>TIME</th>
<th>Nov. 7 (Thu)</th>
<th>TIME</th>
<th>Nov. 8 (Fri)</th>
<th>TIME</th>
<th>Nov. 9 (Sat)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>REGISTRATION/IACRLRD WC MEETING</td>
<td>08:00</td>
<td>REGISTRATION/WC MEETING</td>
<td>08:00</td>
<td>REGISTRATION</td>
</tr>
<tr>
<td>08:50</td>
<td>WELCOME ADDRESS</td>
<td>09:00</td>
<td>MEMORIAL LECTURE 4</td>
<td>09:00</td>
<td>MEMORIAL LECTURE 7</td>
</tr>
<tr>
<td>09:00</td>
<td>KEYNOTE SPEECH</td>
<td>09:00</td>
<td>MEMORIAL LECTURE 5</td>
<td>09:00</td>
<td>MEMORIAL LECTURE 7</td>
</tr>
<tr>
<td>09:45</td>
<td>SESSION 1</td>
<td>09:45</td>
<td>SESSION 5</td>
<td>09:45</td>
<td>SESSION 9</td>
</tr>
<tr>
<td></td>
<td>Virus Associated Hematologic Malignancies</td>
<td></td>
<td>Multiple Myeloma</td>
<td></td>
<td>Myeloproliferative Neoplasms</td>
</tr>
<tr>
<td>10:45</td>
<td>Coffee Break</td>
<td>10:45</td>
<td>Coffee Break</td>
<td>10:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>MEMORIAL LECTURE 1</td>
<td>11:00</td>
<td>MEMORIAL LECTURE 5</td>
<td>11:00</td>
<td>SESSION 10</td>
</tr>
<tr>
<td></td>
<td>Kyungjae Myung, Korea</td>
<td></td>
<td>David G. Maloney, USA</td>
<td></td>
<td>Leukemia Researches in Asian Sector</td>
</tr>
<tr>
<td>11:45</td>
<td>SESSION 2</td>
<td>11:45</td>
<td>SESSION 6</td>
<td>12:20</td>
<td>ADJOURN</td>
</tr>
<tr>
<td></td>
<td>Myelodysplastic Syndromes</td>
<td></td>
<td>Acute Lymphoblastic Leukemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:05</td>
<td>Break</td>
<td>13:05</td>
<td>Break</td>
<td>12:55</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>LUNCHEON SYMPOSIUM 1</td>
<td>13:15</td>
<td>LUNCHEON SYMPOSIUM 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MEMORIAL LECTURE 2</td>
<td>14:05</td>
<td>MEMORIAL LECTURE 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clara Bloomfield, USA</td>
<td></td>
<td>Ravi Bhatia, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>SESSION 3</td>
<td>14:50</td>
<td>SESSION 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute Myeloid Leukemia</td>
<td></td>
<td>Molecular Mechanisms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>Coffee Break</td>
<td>16:10</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>MEMORIAL LECTURE 3</td>
<td>16:25</td>
<td>SESSION 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rüdiger Hehlmann, Germany</td>
<td></td>
<td>Lymphoma/Chronic Lymphocytic Leukemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:10</td>
<td>SESSION 4</td>
<td>17:45</td>
<td>POSTER SESSION/GENERAL ASSEMBLY OF IACRLRD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic Myeloid Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>18:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:40</td>
<td></td>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## SCIENTIFIC PROGRAM

### NOV. 7 (THU)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:50-09:00</td>
<td>Welcome Address</td>
</tr>
<tr>
<td></td>
<td>Dong-Wook Kim (President of IACRLRD, Chair of IACRLRD 2019, The Catholic University of Korea, Korea)</td>
</tr>
<tr>
<td>09:00-09:25</td>
<td><strong>KEYNOTE SPEECH</strong></td>
</tr>
<tr>
<td></td>
<td>Infectious Origins of Some Leukemias &amp; What To Do</td>
</tr>
<tr>
<td></td>
<td>Robert Gallo (University of Maryland, USA)</td>
</tr>
<tr>
<td>09:25-10:45</td>
<td><strong>SESSION 1</strong></td>
</tr>
<tr>
<td></td>
<td>VIRUS ASSOCIATED HEMATOLOGIC MALIGNANCIES</td>
</tr>
<tr>
<td>09:25-09:45</td>
<td>A Novel Epigenetic Drug against Adult T-cell Leukemia</td>
</tr>
<tr>
<td></td>
<td>Toshiki Watanabe (The University of Tokyo, Japan)</td>
</tr>
<tr>
<td>09:45-10:05</td>
<td>TBD</td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>TBD</td>
</tr>
<tr>
<td>10:25-10:45</td>
<td>Can We Cure Adult T Cell Leukemia/Lymphoma?</td>
</tr>
<tr>
<td></td>
<td>Ali Bazzarbachi (American University of Beirut-Medical Center, Lebanon)</td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>11:00-11:45</td>
<td><strong>MEMORIAL LECTURE 1</strong></td>
</tr>
<tr>
<td></td>
<td>The Howard Temin Memorial Lecture</td>
</tr>
<tr>
<td></td>
<td>Translating DNA Repair for Targeting Cancers</td>
</tr>
<tr>
<td></td>
<td>Kyungjae Myung (Institute for Basic Science, Ulsan National Institute of Science and Technology, Korea)</td>
</tr>
<tr>
<td>11:45-13:05</td>
<td><strong>SESSION 2</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MYELODYSPLASTIC SYNDROMES</strong></td>
</tr>
<tr>
<td>11:45-12:05</td>
<td>DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation</td>
</tr>
<tr>
<td></td>
<td>Myunggon Ko (Ulsan National Institute of Science and Technology, Korea)</td>
</tr>
<tr>
<td>12:05-12:25</td>
<td>MDS - The Old and New</td>
</tr>
<tr>
<td></td>
<td>Moshe Mittelman (Tel Aviv Sourasky Medical Center, Israel)</td>
</tr>
<tr>
<td>12:25-12:45</td>
<td>TBD</td>
</tr>
<tr>
<td>12:45-13:05</td>
<td>Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Michael Lübbert (University of Freiburg Medical Center, Germany)</td>
</tr>
<tr>
<td>13:05-13:15</td>
<td>BREAK</td>
</tr>
<tr>
<td>13:15-14:05</td>
<td>LUNCHEON SYMPOSIUM 1</td>
</tr>
<tr>
<td>14:05-14:50</td>
<td><strong>MEMORIAL LECTURE 2</strong></td>
</tr>
<tr>
<td></td>
<td>The Sol Spiegelman Memorial Lecture</td>
</tr>
<tr>
<td></td>
<td>Biological Heterogeneity of AML: Implications for Prognosis and Treatment</td>
</tr>
<tr>
<td></td>
<td>Clara Bloomfield (The Ohio State University, USA)</td>
</tr>
<tr>
<td>14:50-16:10</td>
<td><strong>SESSION 3</strong></td>
</tr>
<tr>
<td></td>
<td><strong>ACUTE MYELOID LEUKEMIA</strong></td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>The Rapidly Evolving Landscape in AML</td>
</tr>
<tr>
<td></td>
<td>Gert Ossenkoppele (Amsterdam University Medical Center, location VUMC, The Netherlands)</td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>Curative Treatment Options for Older Patients with AML</td>
</tr>
<tr>
<td></td>
<td>Hervé Dombret (Saint-Louis Institute for Research/ University of Paris, France)</td>
</tr>
<tr>
<td>15:30-15:50</td>
<td>Development of A Novel FLT3 Inhibitor</td>
</tr>
<tr>
<td></td>
<td>Hitoshi Kiyoi (Nagoya University, Japan)</td>
</tr>
<tr>
<td>15:50-16:10</td>
<td>Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Tyner (Oregon Health &amp; Science University, USA)</td>
</tr>
<tr>
<td>16:10-16:25</td>
<td>COFFEE BREAK</td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
</table>
| 16:25-17:10 | **MEMORIAL LECTURE 3**  
The Frank Rauscher Memorial Lecture  
Approaching Survival of the General Population: The Results of CML Study IV in the Global Context  
Rüdiger Hehlmann (Heidelberg University, Germany) |
| 17:10-18:30 | **SESSION 4**  
**CHRONIC MYELOID LEUKEMIA**  
17:10-17:30  
Next Generation Sequencing for Chronic Myeloid Leukemia  
Susan Brantford (Centre for Cancer Biology, SA Pathology, Australia)  
17:30-17:50  
New Horizon for CML Therapy: Treatment Discontinuation (TFR)  
Giuseppe Saglio (University of Turin, Italy)  
17:50-18:10  
TBD  
18:10-18:30  
TBD  
Jane Apperley (Hammersmith Hospital, UK) |
| 18:40 - 20:10 | **FACULTY SPEAKER DINNER** |
| 09:00-09:45 | **MEMORIAL LECTURE 4**  
The Charlotte Friend Memorial Lecture  
New Models of Human Leukemia  
Connie Eaves (British Columbia Cancer Agency, Canada) |
| 09:45-10:45 | **SESSION 5**  
**MULTIPLE MYELOMA**  
09:45-10:05  
Clinical and Biological Significance of RNA Editing Defect in Myeloma  
Wee Joo Chng (National University Health System, Singapore)  
10:05-10:25  
TBD  
10:25-10:45  
TBD  
Giovanni Martinelli (IRST, Italy) |
| 10:45-11:00 | **COFFEE BREAK** |
| 11:00-11:45 | **MEMORIAL LECTURE 5**  
The Kenneth McCredie Memorial Lecture  
Integrating CART-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes  
David G. Maloney (Fred Hutchinson Cancer Research Center, USA) |
| 11:45-13:05 | **SESSION 6**  
**ACUTE LYMPHOBLASTIC LEUKEMIA**  
11:45-12:05  
Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model  
Itaru Kato (Kyoto University, Japan)  
12:05-12:25  
Targeting Cell Adhesion-mediated Resistance in ALL  
Yong-Mi Kim (University of Southern California, USA)  
12:25-12:45  
Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia  
Dieter Hoelzer (Onkologikum Frankfurt, Germany)  
12:45-13:05  
Philadelphia Chromosome-Positive ALL : Evolving Place for TKIs, Chemotherapy, Targeted Therapy and Transplantation  
François Huguet (University Institute of Cancer, France)  
13:05-13:15 | **BREAK** |
| 13:15-14:05 | **LUNCHEON SYMPOSIUM 2** |
| 14:05-14:50 | **MEMORIAL LECTURE 6**  
The Peter-Hans Hofschneider Memorial Lecture  
Leukemia Stem Cell and Bone Marrow Microenvironment Interactions  
Ravi Bhatia (The University of Alabama at Birmingham, USA) |
| 14:50-16:10 | **SESSION 7**  
**MOLECULAR MECHANISMS**  
14:50-15:10  
Understanding and Targeting the Stem Cell Origins of MDS and AML  
Ulrich Steidl (Albert Einstein College of Medicine - Montefiore Medical Center, USA)  
15:10-15:30  
Genetics and Mechanisms of Chemotherapy Resistance in ALL  
Adolfo Ferrando (Columbia University, USA)  
15:30-15:50  
Clonal Origin of Cancer  
Seishi Ogawa (Kyoto University, Japan)  
15:50-16:10  
Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution  
Semin Lee (Ulsan National Institute of Science and Technology, Korea) |
## SCIENTIFIC PROGRAM

### 16:10-16:25
- **Coffee Break**

### 16:25-17:45
**SESSION 8**
- **16:25-16:45**
  - Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia
  - Gianluca Gaidano (University of Eastern Piedmont, Italy)
- **16:45-17:05**
  - Challenges Today in the Management of CLL
  - Robin Foà ('Sapienza' University of Rome, Italy)
- **17:05-17:25**
  - Management of NK/T-cell lymphoma
  - Seok Jin Kim (Samsung Medical Center, Korea)
- **17:25-17:45**
  - TBD
  - John F. Seymour (Peter MacCallum Cancer Center, Australia)

### 17:45-18:45
- **Poster Session / General Assembly of IACRLRD**

### 19:30-21:00
- **Gala Dinner / Awards**

### NOV. 9 (SAT)

#### 09:00-09:45
**Memorial Lecture 7**
- **Understanding Evolution and Outcomes in Myeloproliferative Neoplasms**
- Jyoti Nangalia (Wellcome Sanger Institute, UK)

#### 09:45-10:45
**SESSION 9**
- **09:45-10:05**
  - 2020 Classification and treatment options of JAK2 CALR and MPL mutated Myeloproliferative Neoplasms
  - Jan Jacques Michiels (Antwerp University Hospital, Belgium)
- **10:05-10:25**
  - TBD
- **10:25-10:45**
  - TBD
  - Hideki Muramatsu (Nagoya University, Japan)

#### 10:45-11:00
- **Coffee Break**

#### 11:00-12:20
**SESSION 10**
- **11:00-11:20**
  - Study of Hematopoiesis Using Zebrafish Model System
  - Yoonsung Lee (Institute for Basic Science, Ulsan National Institute of Science and Technology, Korea)
- **11:20-11:40**
  - Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells
  - Kazuhito Naka (Hiroshima University, Japan)
- **11:40-12:00**
  - Overview of CAR-T
  - Xiaojun Huang (Peking University People’s Hospital, China)
- **12:00-12:20**
  - Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
  - Jae Park (Memorial Sloan Kettering Cancer Center, USA)

#### 12:20 - 12:55
- **Adjourn**
CALL FOR ABSTRACT

The IACRLRD 2019 Organizing Committee invites all interested Leukemia and Related Disease Researchers to submit poster abstracts. All abstracts will be reviewed by the Scientific Committee and, if accepted, the author will be asked to present during the Poster Session on Nov. 8 (Fri). Abstracts should be submitted online. Please follow the below instructions. For any inquiries, please contact the Secretariat (secretariat@iacrlrd2019.org).

IMPORTANT DATE

**AUG. 30, 2019**

Abstract Submission Deadline

**ABSTRACT SUBMISSION TOPICS**

- Virus Associated Hematologic Malignancies
- Multiple Myeloma
- Myeloproliferative Neoplasms
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Leukemia Research in the Asia Sector
- Acute Myeloid Leukemia
- Molecular Mechanisms
- Chronic Myeloid Leukemia
- Lymphoma/Chronic Lymphocytic Leukemia

**NOTIFICATION OF ACCEPTANCE**

- All submitted abstracts will be reviewed by the Scientific Program Committee according to reviewing procedures.
- Notification of acceptance will be sent by e-mail to corresponding, presenting and abstract submitting authors by September 10, 2019.
- The presenting author should reply to the acceptance notification to confirm attendance.

**ABSTRACT WITHDRAWAL**

- If the presenting author of an accepted abstract does not register by September 13, 2019, the abstract will be automatically withdrawn from the final program.
- If you have to withdraw an abstract, please notify the secretariat (secretariat@iacrlrd2019.org) as soon as possible.
TRAVEL GRANTS

The IACRLRD 2019 Organizing Committee will offer the Travel Grant Award to presenters whose abstracts have been accepted. When you submit an abstract, you can apply for the Travel Award. The secretariat will contact awardees individually.

GRANT
Awardees will receive a travel grant in the amount of USD 1,500.

ELIGIBILITY
1. Presenters of accepted abstracts are eligible for the travel grant.
2. Abstracts must be presented by awardees at IACRLRD 2019.
3. Presenters need to register for the conference. (Registration fees will not be waived)

BEST POSTER AWARDS

The IACRLRD 2019 Organizing Committee will give Best Poster Awards to outstanding papers chosen from the Poster Session on Nov. 8 (Fri). You may view the presentation schedule in the Meeting Program later. Awardees will be announced on Nov. 8 (Fri) and the award ceremony will be held at the closing ceremony on Nov. 9 (Sat).

GRANT
Awardees will receive an award in the amount of USD 500.

ELIGIBILITY
1. Presenters of accepted abstracts are eligible for the Best Poster Award.
2. Abstracts must be presented by awardees at IACRLRD 2019.
3. Presenters need to register for the conference. (Registration fees will not be waived)
SOCIAL PROGRAM

FACULTY SPEAKER DINNER
Date/Time  Nov. 7 (Thu), 18:40 - 20:10
Place    Namsan Room, Grand Hyatt Seoul, Korea
Menu     Standing Cocktail

GALA DINNER / AWARDS
Date/Time  Nov. 8 (Fri), 19:30 - 21:00
Place    Grand Ballroom, Grand Hyatt Seoul, Korea
Fee      Included in the registration fee
Menu     Western Full Course

TOURS
Tours will be arranged by a third-party travel agency as optional programs. If you would like to participate in a tour, please visit the IACRLRD 2019 website (www.iacrlrd2019.org).

HALF DAY DMZ TOUR

CHARMING KOREA AFTERNOON TOUR

ROYAL PALACE AND SHOPPING FULL DAY TOUR
REGISTRATION

IMPORTANT DATE

SEP. 13, 2019
Pre-Registration Deadline

REGISTRATION FEES (OVERSEAS)

<table>
<thead>
<tr>
<th>Categories</th>
<th>Pre-Registration (by September 13, 2019)</th>
<th>Onsite Registration (November 7-9, 2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IACRLRD Member</td>
<td>USD 150</td>
<td>USD 250</td>
</tr>
<tr>
<td>IACRLRD Non-Member</td>
<td>USD 300</td>
<td>USD 400</td>
</tr>
<tr>
<td>Fellow/Student</td>
<td>Free</td>
<td>Free</td>
</tr>
</tbody>
</table>

* Students are requested to submit proof of enrollment or student ID/certificate to verify their status to the Secretariat by e-mail.

ACCOMMODATIONS

The IACRLRD 2019 Organizing Committee has selected hotels in different rate categories for IACRLRD 2019 participants. To take advantage of the special rates for hotel accommodations secured by the committee, please visit the IACRLRD 2019 website (www.iacrlrd2019.org).
VENUE

GRAND HYATT SEOUL, KOREA

Grand Hyatt Seoul, in the heart of the nation’s capital, is set amidst 18 acres of beautifully landscaped gardens at the foot of historic Mt. Namsan.

Commanding breathtaking views of the Han River to the south and Mt. Namsan to the north, the hotel is only minutes away from the downtown commercial district and within walking distance of Itaewon, one of the most popular tourist attractions.

The hotel is 70 minutes away from Incheon International Airport, 50 minutes from Gimpo Domestic Airport, 20 minutes from the Samsung-dong business hub, with most all of the city’s key districts within proximity to the hotel.